For citations:
Ionova T.I., Nikitina T.P., Lomaia E.G., Kuchma G.B., Machyulaytene E.R., Usacheva E.I., Shnaider T.V., Rodionova A.Yu., Kurbatova K.A. Quality of life, symptom profile and clinical efficacy of second-line treatment with dasatinib in patients with imatinib-resistant or -intolerant chronic myeloid leukemia: results of 2-year follow-up. Oncohematology. 2015;10(3):18-27. (In Russ.) https://doi.org/10.17650/1818-8346-2015-10-3-18-27